Novastan: Began a 750-patient Phase II trial. The primary end point is a composite of death and adverse cardiac events; secondary end point is patency after 90

Texas Biotechnology Corp. (TXB), Houston
Product:

Read the full 69 word article

How to gain access

Continue reading with a
two-week free trial.